神经原纤维缠结分期与阿尔茨海默症状进展速率:基于尸检队列的建模及临床试验设计应用
高Braak分期者逻辑记忆评分每年多下降0.38单位(95%CI -0.70至-0.06;模拟300例临床试验,以CDR-SB斜率改善20%为终点,高Braak分期入组时把握度89%,未用分期时仅29%。
要点
- Braak分期可独立预测阿尔茨海默临床进展速率。
- 高Braak分期者逻辑记忆年下降额外0.38单位。
- 用Braak分期入组可大幅提升试验把握度至89%。
核心结论
- 神经原纤维缠结分期知识可显著改善临床试验把握度并等效减少所需样本量。
研究设计与样本
- 临床评估在31个国家衰老研究所阿尔茨海默病中心进行。
- 采用反向时间纵向建模结合潜在类别估计以调整未测量异质性。
主要发现
- 较高教育水平与较低CDR-SB相关(β=-0.19;P<.001)。
- 频繁 vs 中等神经炎斑块与较高CDR-SB相关(β=1.64;P<.001)及较低逻辑记忆评分相关(β=-1.07;P=.005)。
- 调整斑块、死亡年龄、性别、教育和APOE基因型后,临床和认知评分变化速率随Braak分期而异。
- 高 vs 低Braak分期比较,逻辑记忆评分每年额外下降0.38单位(95%CI -0.70至-0.06;P=.02)。
关键数值与推荐
- 300例临床试验以CDR-SB变化斜率改善20%为终点,全部高Braak分期入组时把握度89%,未用Braak分期时29%。
临床怎么用
- 可将Braak分期(如tau PET所提供信息)用于临床试验入组筛选以提升效率。
- 临床咨询中可参考神经原纤维缠结分期预判进展速率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The heterogeneity of rate of clinical progression among patients with Alzheimer disease leads to difficulty in providing clinical counseling and diminishes the power of clinical trials using disease-modifying agents. OBJECTIVE: To gain a better understanding of the factors that affect the natural history of progression in Alzheimer disease for the purpose of improving both clinical care and clinical trial design. DESIGN, SETTING, AND PARTICIPANTS: A longitudinal cohort study of aging from 2005 to 2014 in the National Alzheimer Coordinating Center. Clinical evaluation of the participants was conducted in 31 National Institute on Aging's Alzheimer Disease Centers. Nine hundred eighty-four participants in the National Alzheimer Coordinating Center cohort study who died and underwent autopsy and met inclusion and exclusion criteria. MAIN OUTCOMES AND MEASURES: We sought to model the possibility that knowledge of neurofibrillary tangle burden in the presence of moderate or frequent plaques would add to the ability to predict clinical rate of progression during the ensuing 2 to 3 years. We examined the National Alzheimer Coordinating Center autopsy data to evaluate the effect of different neurofibrillary tangle stages on the rates of progression on several standard clinical instruments: the Clinical Dementia Rating Scale sum of boxes, a verbal memory test (logical memory), and a controlled oral word association task (vegetable naming), implementing a reverse-time longitudinal modeling approach in conjunction with latent class estimation to adjust for unmeasured sources of heterogeneity. RESULTS: Several correlations between clinical variables and neurocognitive performance suggest a basis for heterogeneity: Higher education level was associated with lower Clinical Dementia Rating Scale sum of boxes (β = -0.19; P < .001), and frequent vs moderate neuritic plaques were associated with higher Clinical Dementia Rating Scale sum of boxes (β = 1.64; P < .001) and lower logical memory score (β = -1.07; P = .005). The rate of change of the clinical and cognitive scores varied depending on Braak stage, when adjusting for plaques, age of death, sex, education, and APOE genotype. For example, comparing high vs low Braak stage with other variables fixed, the logical memory score decreased a substantial 0.38 additional units per year (95% CI, -0.70 to -0.06; P = .02). Using these data, we estimate that a 300-participant clinical trial with end point of a 20% improvement in slope in rate of change of Clinical Dementia Rating Scale sum of boxes has 89% power when all participants in the trial are from the high Braak stage, compared with 29% power if Braak stage had not used for eligibility. CONCLUSIONS AND RELEVANCE: We found that knowledge of neurofibrillary tangle stage, modeled as the sort of information that could be available from tau positron-emission tomography scans and its use to determine eligibility to a trial, could dramatically improve the power of clinical trials and equivalently reduce the required sample sizes of clinical trials.
引用
- Qian J, Hyman BT, Betensky RA, et al. Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design. JAMA Neurol. 2017. PMID: 28288263. doi:10.1001/jamaneurol.2016.5953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。